Table of Content

1. Research Methodology


2. Introduction To CD3 Directed Drugs
2.1 Overview
2.2 History & Evolution of CD3 Directed Drugs


3. Mechanism of Action of CD3 Antibodies
3.1 As Immunosuppressive Therapy
3.2 As Immune Activation Therapy


4. Application of CD3 Antibodies By Indication
4.1 Cancer
4.2 Inflammatory & Autoimmune Conditions


5. Global CD3 Antibodies Market & Clinical Trials Outlook
5.1 Current Market Trends, Developments & Clinical Trials Assessment
5.2 Sales Analysis
5.3 Future Market Opportunities


6. CD3 Targeting Antibodies Market Landscape by Region
6.1 US
6.2 EU
6.3 Canada
6.4 UK
6.5 Japan


7. Approved CD3 Antibody Dosage, Patent, Price & Sales Insight
7.1 Blincyto – 1st Approved CD3 Antibody
7.2 Kimmtrak – 2nd Approved CD3 Antibody
7.3 Tecvayli – 3rd Approved CD3 Antibody
7.4 Others (6 More CD3 Antibodies)


8. Global CD3 Antibodies Clinical Trials Overview
8.1 By Company
8.2 By Country
8.3 By Indication
8.4 By Phase
8.5 By Patient Segment


9. Global CD3 Antibodies Clinical Trials Insight By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration


10. Marketed CD3 Antibodies Clinical Insight By Company & Indication


11. Global CD3 Inhibitors Market Dynamics
11.1 Drivers & Opportunities
11.2 Challenges & Restraints


12. Competitive Landscape
12.1 Abpro Therapeutics
12.2 Adagene
12.3 Amgen
12.4 Astellas Pharma
12.5 Beijing Mabworks Biotech
12.6 BioAtla
12.7 Genentech
12.8 Genmab
12.9 Harbour BioMed
12.10 Harpoon Therapeutics
12.11 IGM Biosciences
12.12 Immunocore
12.13 Integral Molecular
12.14 ITabMed
12.15 Janssen Research & Development
12.16 Janux Therapeutics
12.17 KeyMed Biosciences
12.18 Light Chain Bioscience
12.19 Linton Pharm
12.20 MacroGenics
12.21 Memorial Sloan-Kettering Cancer Center
12.22 Pfizer
12.23 Qilu Pharmaceutical
12.24 Regeneron Pharmaceuticals
12.25 Roche
12.26 Sichuan Baili Pharmaceutical
12.27 SystImmune
12.28 Takeda
12.29 Xencor
12.30 Zymeworks



List of Tables

Table 7-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 7-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 7-3: Blincyto – Recommended Dose Modifications
Table 7-4: Kimmtrak - Recommended Dosage for Treatment of Unresectable or
Metastatic Uveal Melanoma
Table 7-5: Kimmtrak - Dose Modifications for Adverse Reactions
Table 7-6: Tecvayli - Dosing Schedule
Table 7-7: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 7-8: Tzield - Recommended Dosage and Administration
Table 7-9: Lunsumio - Recommended Dose & Schedule for 21-Day Treatment Cycles
Table 7-10: Lunsumio - Recommendations for Management of Cytokine Release
Syndrome
Table 7-11: Lunsumio - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-12: Lunsumio - Recommended Dosage Modification for Adverse Reactions
Table 7-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 7-14: Columvi - Recommendations for Management of Cytokine Release
Syndrome
Table 7-15: Columvi - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-16: Columvi - Recommended Dosage Modification for Adverse Reactions
Table 7-17: Epkinly - Dosage Schedule
Table 7-18: Epkinly - Recommendations for Management of Cytokine Release
Syndrome
Table 7-19: Epkinly - Recommendations for Management of Immune Effector Cell-
Associated Neurotoxicity Syndrome (ICANS)
Table 7-20: Epkinly - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-21: Talvey - Weekly Dosing Schedule
Table 7-22: Talvey – Biweekly Dosing Schedule
Table 7-23: Talvey - Recommendations for Management of CRS
Table 7-24: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 7-25: Talvey - Recommendations for Management of Neurologic Toxicity
(excluding ICANS)
Table 7-26: Talvey - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-27: Elrexfio - Dosing Schedule
Table 7-28: Elrexfio - Recommendations for Management of CRS
Table 7-29: Elrexfio - Recommended Dosage Modifications for Other Adverse
Reactions